Idorsia IDIA

SWX: IDIA | ISIN: CH0363463438 11/12/2024

1,506 CHF (+12,64%)

(+12,64%) 11/12/2024

Grafiek Idorsia Ltd

Grafiek Idorsia Ltd

1 dag1d 12,64%
1 week1w 46,36%
1 maand1m 58,28%
3 maanden3m -8,45%
6 maanden6m -25,45%
1 jaar1j -22,69%
5 jaar5j -94,80%

Idorsia Ltd in het nieuws

Toon enkel gratis nieuws

27 november 2024 · Idorsia enters into exclusive negotiations for global rights to aprocitentan · Persbericht

11 november 2024 · Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions · Persbericht

29 oktober 2024 · Idorsia announces financial results for the first nine months of 2024 · Persbericht

16 oktober 2024 · New data on aprocitentan to be presented at the ASN Kidney Week 2024 · Persbericht

17 september 2024 · Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024 · Persbericht

5 september 2024 · New data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024 · Persbericht

2 september 2024 · Amended terms of Idorsia’s 2024 convertible bonds become effective · Persbericht

25 juli 2024 · Idorsia announces financial results for the first half 2024 · Persbericht

18 juli 2024 · Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call · Persbericht

1 juli 2024 · Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension · Persbericht

Profiel Idorsia Ltd

CEO: Jean-Paul Clozel

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe